Codexis (CDXS) Net Income towards Common Stockholders (2010 - 2026)

Codexis' (CDXS) quarterly Net Income towards Common Stockholders came in at -$8.7 million in Q1 2026, up 57.93% year-on-year from -$5.5 million in Q1 2025, and down 190.66% quarter-over-quarter from $9.6 million in Q4 2025.

Codexis (CDXS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Codexis' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8.7 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 57.93% year-over-year to -$8.7 million in Q1 2026; TTM through Mar 2026 was -$32.0 million, a 57.04% increase from a year earlier, with the FY2025 full-year figure at -$44.0 million, up 32.63% from the prior year.
  • Net Income towards Common Stockholders slipped to -$8.7 million in Q1 2026 per CDXS's latest filing, from $9.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $9.6 million in Q4 2025 and bottomed at -$34.9 million in Q3 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$11.5 million (2023), against an average of -$13.4 million.
  • Across the five-year window, Net Income towards Common Stockholders slumped 545.28% in 2022 and surged 192.53% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$12.6 million in 2022, then soared by 42.94% to -$7.2 million in 2023, then tumbled by 44.27% to -$10.4 million in 2024, then jumped by 192.53% to $9.6 million in 2025, then slumped by 190.66% to -$8.7 million in 2026.
  • Per Business Quant, the three latest CDXS Net Income towards Common Stockholders figures stand at -$8.7 million (Q1 2026), $9.6 million (Q4 2025), and -$19.6 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Codexis 135.70 Mn 70.56 Mn 13.18 Mn -8.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.70 Mn
Dec 31, 2025 9.60 Mn
Sep 30, 2025 -19.62 Mn
Jun 30, 2025 -13.27 Mn
Mar 31, 2025 -20.69 Mn
Dec 31, 2024 -10.38 Mn
Sep 30, 2024 -20.64 Mn
Jun 30, 2024 -22.76 Mn
Mar 31, 2024 -11.51 Mn
Dec 31, 2023 -7.19 Mn
Sep 30, 2023 -34.91 Mn
Jun 30, 2023 -11.52 Mn
Mar 31, 2023 -22.62 Mn
Dec 31, 2022 -12.60 Mn
Sep 30, 2022 -9.99 Mn
Jun 30, 2022 -2.64 Mn
Mar 31, 2022 -8.36 Mn
Dec 31, 2021 -10.19 Mn
Sep 30, 2021 2.24 Mn
Jun 30, 2021 -4.27 Mn